A complex of α6 integrin and E‐cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin‐like 6

Homing of colorectal cancer (CRC) cells to the liver is a non‐random process driven by a crosstalk between tumour cells and components of the host tissue. Here we report the isolation of a liver metastasis‐specific peptide ligand (CGIYRLRSC) that binds a complex of E‐cadherin and α 6 integrin on the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EMBO molecular medicine 2012-11, Vol.4 (11), p.1156-1175
Hauptverfasser: Marchiò, Serena, Soster, Marco, Cardaci, Sabrina, Muratore, Andrea, Bartolini, Alice, Barone, Vanessa, Ribero, Dario, Monti, Maria, Bovino, Paola, Sun, Jessica, Giavazzi, Raffaella, Asioli, Sofia, Cassoni, Paola, Capussotti, Lorenzo, Pucci, Piero, Bugatti, Antonella, Rusnati, Marco, Pasqualini, Renata, Arap, Wadih, Bussolino, Federico
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Homing of colorectal cancer (CRC) cells to the liver is a non‐random process driven by a crosstalk between tumour cells and components of the host tissue. Here we report the isolation of a liver metastasis‐specific peptide ligand (CGIYRLRSC) that binds a complex of E‐cadherin and α 6 integrin on the surface of CRC cells. We identify angiopoietin‐like 6 protein as a peptide‐mimicked natural ligand enriched in hepatic blood vessels of CRC patients. We demonstrate that an interaction between hepatic angiopoietin‐like 6 and tumoural α 6 integrin/E‐cadherin drives liver homing and colonization by CRC cells, and that CGIYRLRSC inhibits liver metastasis through interference with this ligand/receptor system. Our results indicate a mechanism for metastasis whereby a soluble factor accumulated in normal vessels functions as a specific ligand for circulating cancer cells. Consistently, we show that high amounts of coexpressed α 6 integrin and E‐cadherin in primary tumours represent a poor prognostic factor for patients with advanced CRC.
ISSN:1757-4676
1757-4684
DOI:10.1002/emmm.201101164